Urinary alpha-naphthyl acetate esterases: a preliminary screening test for bladder cancer

Area of Science:

• Biochemistry
• Urology
• Oncology

Background:

• Urinary enzyme activity can serve as a biomarker for urologic diseases.
• Bilharzia (schistosomiasis) is endemic in many regions and is associated with an increased risk of bladder cancer.

Purpose of the Study:

• To evaluate the diagnostic potential of urinary alpha-naphthyl acetate esterase activity for bladder cancer.
• To compare enzyme activity in patients with benign urologic diseases versus bladder cancer, considering bilharzial status.

Main Methods:

• Measurement of urinary alpha-naphthyl acetate esterase activity in healthy controls, patients with benign urologic diseases (bilharzial and nonbilharzial), and bladder cancer patients (bilharzial and nonbilharzial).
• Statistical analysis to compare enzyme activity levels across different patient groups.
• Determination of a cutoff level (50 units) for discriminating between benign and malignant urologic conditions.

Main Results:

• All patient groups exhibited elevated urinary enzyme activity compared to healthy controls.
• Significantly higher enzyme activity was observed in bladder cancer patients (both bilharzial and nonbilharzial) compared to those with benign urologic diseases.
• A cutoff of 50 units demonstrated over 90% specificity and sensitivity for detecting bladder cancer, with minimal false positives and negatives.

Conclusions:

• Urinary alpha-naphthyl acetate esterase activity is a promising preliminary screening marker for bladder cancer.
• This non-invasive test shows high accuracy and can be applied to both bilharzial and nonbilharzial populations.
• The findings support the use of this enzyme assay as an initial step in diagnosing bladder cancer.